Pioneering new therapies for diseases of chromatin dysfunction.


A new paradigm of
drug Discovery

targeting chromatin networks

There is a necessity for new types of treatments in chromatin driven diseases like pediatric diffuse midline glioma (DMG).
TippingPoint has found a way to recapitulate the disease driving chromatin interactions in a test tube and uniquely target these aberrant interactions in disease.

Background blue scribble


A new approach to  therapeutics

TippingPoint Biosciences' mission is to treat diseases caused by dysfunctional genome chromatin packaging that are difficult to target using conventional approaches.

What is chromatin?

Chromatin is the packaging of DNA inside of a cell nucleus.

Chromatin structure dictates cell function and identity.

Human grabbing ADN
Human grabbing adn
Solution icon black circle with white icon in the midle


Unleashing the Potential of DNA chromatin Packaging
Many diseases are driven by dysfunctional chromatin networks.
A Paradigm Shift in Drug
We specifically target the aberrant chromatin network in disease.
Unveiling a New Era of
We develop a new class of molecules to target diseases of high unmet need.

Team & advisory

Our multidisciplinary team combines all the verticals needed to make it work

Want to join us?

Open positions

Make a difference with us

There are no open positions at this moment...

Check back in a while or write to us.


Stay informed and updated

Stay informed to empower yourself with the latest knowledge and insights.

Top arrow

Let us know what
you think!

We're excited to connect with you. Please feel free to reach out anytime!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.